SSGA Active Trust has released its latest financial report, revealing significant figures that reflect its current standing in the investment management sector. As of August 31, 2026, the trust reported total assets of approximately $40.25 million, with net assets totaling around $39.42 million. This filing underscores the trust's commitment to maintaining a robust asset base while effectively managing its liabilities.
Founded as an investment entity, SSGA Active Trust is part of a competitive landscape that includes numerous firms focused on asset management. The trust's recent filing, dated October 28, 2026, provides insights into its financial health and investment strategies. The details shared in this report are crucial for understanding how SSGA is navigating the evolving investment landscape.
Background
SSGA Active Trust is classified under the investment entity category, focusing on managing various investment portfolios. The trust operates under the Central Index Key (CIK) number 0001516212. Its recent filings include multiple submissions on October 28, 2026, specifically in the NPORT-P form type, which details its financial standing as of August 31, 2026.
What the Filing Says
The latest filing highlights key financial metrics, including total assets of $40,250,586.32 and total liabilities of $832,778.50. The net assets reported are $39,417,807.82, indicating a solid position for the trust. The filing does not provide additional commentary or insights beyond these figures.
Impact
This financial update may impact various stakeholders, including investors, analysts, and competitors in the asset management industry. The reported figures suggest that SSGA Active Trust is effectively managing its assets and liabilities, which could influence investor confidence and competitive strategies within the sector.
What's Next
The filing does not indicate what happens next for SSGA Active Trust. However, continued monitoring of its financial performance and potential future filings will be essential for stakeholders looking to understand the trust's trajectory.
Read Next
van Houte Hans Reports Stock Transactions at Nurix Therapeutics
Hansen Gwenn Acquires and Sells Shares at Nurix Therapeutics
Drouillard Vincent Amends Filing to Correct Share Sale Details
Drouillard Vincent reports sale of 10,000 shares in AerCap
Gilead Sciences CEO Daniel O'Day Executes Multiple Stock Sales
Le Peuch Olivier Sells 25,000 Shares of SLB Limited





